Introduction. Multiple sclerosis (MS) is a neurodegenerative demyelinating disease characterized by nervous system injuries. It has been calculated that about 2.5-3 million people worldwide are diagnosed with MS, including 600,000 in Europe and 110,000 in Italy. On a frequency basis, MS is the second neurological disease in young adults and the first as chronic inflammatory disease. The quantitative and qualitative analysis of the full extent of the “MS issue” regarding a country population, it can provide a contribution to enhance MS knowledge and simultaneously create the basis for further research and for an adequate health programme designed to meet the welfare and social needs of italian people with MS.


  • Set an universal census of patients updated on a systematic and ongoing way in order to obtain accurate estimates of prevalence and incidence of the disease at regional and national level with the purpose of contributing to a Country definite strategic programme of MS prevention, diagnosis, treatment, health planning, quality of care assessment and health care evaluation.
  • Gather information for planning research studies in specific projects. Particularly, pharmacovigilance studies to identify safety, tolerability and efficacy associated with short- and long-term immunosuppressive and immunomodulatory treatments, as well as studies on prognostic factors and biomarkers related to disease progression, response to treatment and mortality.

Type of study. No-profit, multi-center longitudinal observational study

Population. Cohort of more than 70,000 patients with multiple sclerosis

Centers. 130 centers for the diagnosis and treatment of multiple sclerosis

Promoter. Fondazione Italiana Sclerosi Multipla in partnership with IRCCS Mario Negri

Funding. Fondazione Italiana Sclerosi Multipla

Status. Ongoing Study